Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-10-05

Clinical Trial Update: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority [Phase 3]

View source ↗

Summary

A Phase 3 completed trial comparing vitamin K antagonists, rivaroxaban, and aspirin for rheumatic heart disease in rheumatic heart disease patients, focusing on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aspirin (Aspirin)
  • Rivaroxaban (rivaroxaban)
  • Vitamin K antagonists

Snippet

Sponsor: Population Health Research Institute | Conditions: Rheumatic Heart Disease | Phase 3 | Status: COMPLETED